

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for treating a subject having inflammation associated with neurotrauma, said method comprising administering to the [[a]] subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory salicylate drug (NSAID), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof non-inhibitory of platelets, wherein said NSAID is intrathecally delivered by intrathecal catheter so as to reduce the inflammation associated with the neurotrauma.

2-3. (Canceled)

4. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

5. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

6. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

7. (Original) A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

8-28. (Canceled)

29. (Currently Amended) A method for treating a subject having inflammation associated with neuronal injury, said method comprising intrathecally administering by intrathecal catheter to the [[a]] subject having neuronal injury a therapeutically effective amount of a non-steroidal, anti-inflammatory salicylate drug (NSAID), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof that is non-inhibitory of platelets so as reduce the inflammation associated with the neuronal injury.

30. (Original) A method according to claim 29, wherein the NSAID is intraventricularly delivered.

31. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

32. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

33. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

34. (Original) A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

35. (Previously Presented) A method according to claim 29, wherein the neuronal injury is caused by Lupus, inflammatory neuropathy, infection, transverse myelitis, Parkinson's disease, CNS vasculitis, or Alzheimer's disease.

36. (Currently Amended) A method for treating a subject having inflammation associated with neurotrauma, said method comprising administering to the [[a]] subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory salicylate drug (NSAID), or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof non-inhibitory of platelets, wherein said NSAID is intraventricularly delivered by intraventricular catheter so as to reduce the inflammation associated with the neurotrauma.

37. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

38. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

39. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

40. (Previously Presented) A method according to claim 36, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

41. (Currently Amended) A method for treating a subject having inflammation associated with neurotrauma, said method comprising administering to the [[a]] subject having neurotrauma a therapeutically effective amount of choline magnesium trisalicylate, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof so as to reduce the inflammation associated with the neurotrauma.

42. (Currently Amended) A method for treating a subject having inflammation associated with neurotrauma, said method comprising administering to a subject having said neurotrauma a therapeutically effective amount of a non-acetylated salicylate drug or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof so as to reduce the inflammation associated with the neurotrauma.